Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00048074
Registration number
NCT00048074
Ethics application status
Date submitted
24/10/2002
Date registered
25/10/2002
Date last updated
3/02/2016
Titles & IDs
Public title
DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
Query!
Scientific title
A Randomized, Double-blind Study Comparing the Effect of Different Treatment Regimens of Intravenous Bonviva on Lumbar Bone Mineral Density in Women With Osteoporosis
Query!
Secondary ID [1]
0
0
BM16550
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Post Menopausal Osteoporosis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoporosis
Query!
Reproductive Health and Childbirth
0
0
0
0
Query!
Menstruation and menopause
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ibandronate [Bonviva/Boniva]
Treatment: Drugs - ibandronate [Bonviva/Boniva]
Treatment: Drugs - ibandronate [Bonviva/Boniva]
Experimental: 1 - oral placebo daily and IV ibandronate 2 mg q 2 mo
Experimental: 2 - oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
Experimental: 3 - oral placebo daily and IV ibandronate 3 mg q 3 mo
Treatment: Drugs: ibandronate [Bonviva/Boniva]
2mg iv every 2 months
Treatment: Drugs: ibandronate [Bonviva/Boniva]
2.5mg po daily
Treatment: Drugs: ibandronate [Bonviva/Boniva]
3mg iv every 3 months
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Relative Percent Change From Baseline in Mean Bone Mineral Density (BMD) of Lumbar Spine (L2-L4) at 12 Months
Query!
Assessment method [1]
0
0
BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 12. The change in BMD was defined as the relative difference between the last individual measurement available at 12 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline)
Query!
Timepoint [1]
0
0
Baseline and Month 12
Query!
Secondary outcome [1]
0
0
Relative Percent Change From Baseline in Mean BMD of Lumbar Spine (L2-L4) at 24 Months
Query!
Assessment method [1]
0
0
BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at the time of screening and at Month 24. The change in BMD was defined as the relative difference between the last individual measurement available at 24 months and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year - BMD at Baseline) / (BMD at Baseline)
Query!
Timepoint [1]
0
0
Baseline and Month 24
Query!
Secondary outcome [2]
0
0
Absolute Change From Baseline in Mean BMD of Lumbar Spine (L2 - L4) at Month 12 and Month 24
Query!
Assessment method [2]
0
0
BMD was measured by a single dual-energy x-ray absorptiometry (DXA) scan of the lumbar spine at screening, Month 12 and Month 24. The absolute change from Baseline in mean BMD of the lumbar spine (L2-L4) was defined as the difference between the last individual measurement available at Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [2]
0
0
Baseline, Month 12 and Month 24
Query!
Secondary outcome [3]
0
0
Relative Percent Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24
Query!
Assessment method [3]
0
0
BMD was measured by a single DXA scan of the proximal femur at the time of screening, Month 12 and Month 24.The change in BMD of the proximal femur (total hip, trochanter, femoral neck) was defined as the relative difference between the last individual measurement available at Month 12 or Month 24and Baseline, using the following formula: Relative change = 100 x (BMD at 1 year/2year - BMD at Baseline) / (BMD at Baseline). BMD of fractured bones that could impact the scan area were not taken into account. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [3]
0
0
Baseline, Month 12 and Month 24
Query!
Secondary outcome [4]
0
0
Absolute Change From Baseline in BMD of Proximal Femur (Consisting of Total Hip, Trochanter, and Femoral Neck) at Month 12 and 24
Query!
Assessment method [4]
0
0
BMD was measured by a single DXA scan of the proximal femur at the time of screening, Month 12 and Month 24. The absolute change in BMD was defined as the difference between the last individual measurement available at Month 12 or Month 24 and Baseline. BMD of fractured bones that could impact the scan area were not taken into account. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [4]
0
0
Baseline, Month 12 and Month 24
Query!
Secondary outcome [5]
0
0
Relative Change From Baseline in Serum C-telopeptide of Alpha-chain of Type I Collagen (CTX) at Month 6, 12, and 24
Query!
Assessment method [5]
0
0
Serum CTX, a biochemical marker of bone resorption, was measured using the Elecsys s-CTX-I assay, an electrochemiluminescence immunoassay (ECLIA) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The change in serum CTX was defined as the relative difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline, using the following formula: Relative change = 100 x (CTX at Month 6/Month 12/Month 24- CTX at Baseline) / (CTX at Baseline). Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [5]
0
0
Baseline, At Month 6, 12, and 24.
Query!
Secondary outcome [6]
0
0
Absolute Change From Baseline in Serum CTX at Month 6, 12, and 24
Query!
Assessment method [6]
0
0
Serum CTX, a biochemical marker of bone resorption, was measured using the Elecsys s-CTX-I assay, an electrochemiluminescence immunoassay (ECLIA) technique. Samples for serum CTX measurements were collected from participants immediately prior to their IV dosing. Thus, the values reported here represent trough or residual values taken at the end of the 2 month or 3 month IV dosing interval. The absolute change from Baseline in serum CTX was defined as the difference between the last individual measurement available at Month 6 or Month 12 or Month 24 and Baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [6]
0
0
Baseline, At Month 6, 12, and 24.
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Mean Lumbar Spine (L2 - L4) BMD Above or Equal to Baseline at Month 12 and 24
Query!
Assessment method [7]
0
0
A participant is a responder if the mean lumber spine (L2 - L4) BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [7]
0
0
At Month 12 and 24
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Total Hip BMD Above or Equal to Baseline at Month 12 and 24
Query!
Assessment method [8]
0
0
A participant is a responder if the mean total hip BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [8]
0
0
At Month 12 and 24
Query!
Secondary outcome [9]
0
0
Percentage of Participants With Trochanter BMD Above or Equal to Baseline at Month 12 and 24
Query!
Assessment method [9]
0
0
A participant is a responder if the mean trochanter BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [9]
0
0
At Month 12 and 24
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Femoral Neck BMD Above or Equal to Baseline at Month 12 and 24
Query!
Assessment method [10]
0
0
A participant is a responder if the mean femoral neck BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [10]
0
0
At Month 12 and 24
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Mean Total Hip and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24
Query!
Assessment method [11]
0
0
A participant is a responder if the mean total hip and mean lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [11]
0
0
At Month 12 and 24
Query!
Secondary outcome [12]
0
0
Percentage of Participants With Mean Trochanter and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24
Query!
Assessment method [12]
0
0
A participant is a responder if the mean trochanter and lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [12]
0
0
At Month 12 and 24
Query!
Secondary outcome [13]
0
0
Percentage of Participants With Mean Femoral Neck and Lumbar Spine BMD Above or Equal to Baseline at Month 12 and 24
Query!
Assessment method [13]
0
0
A participant is a responder if the mean femoral neck and lumbar spine BMD had remained the same or increased above baseline. Only participants with data available at particular timepoint were analyzed.
Query!
Timepoint [13]
0
0
At Month 12 and 24
Query!
Secondary outcome [14]
0
0
Number of Participants Who Experienced Any Adverse Events (AEs) or Serious Adverse Events (SAEs)
Query!
Assessment method [14]
0
0
An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
Query!
Timepoint [14]
0
0
Approximately 2 years
Query!
Secondary outcome [15]
0
0
Number of Participants With Any Marked Abnormality in Laboratory Parameters
Query!
Assessment method [15]
0
0
Marked laboratory test value abnormalities (high and low) are those which exceed the marked reference range (i.e., a reference range greater than the standard reference range) and which also represents a clinically relevant change from baseline of at least a designated amount. The indicated abnormal laboratory parameters (along with their marked reference range) are as follows: low and high Hematocrit (0.36 - 0.60 fraction), low and high hemoglobin (11.0 - 20.0 g/dL), low and high platelets (100 - 700 * 10^9/L), low and high white blood cell (WBC) (3.0 - 18.0 * 10^9/L), high alanine aminotransferase (ALAT) (0 - 60 U/L), high blood urea nitrogen (BUN) (0 - 14.3 mmol/L) , high creatinine (0 - 154 mmol/L), low albumin (27.0 - 48.0 g/L), low and high chloride (95 - 115 mmol/L), low potassium (3.0 - 6.0 mmol/L), low sodium (130 - 150 mmol/L), high calcium (2.00 - 2.90 mmol/L), low and high phosphate (0.75 - 1.60 mmol/L).
Query!
Timepoint [15]
0
0
Approximately 2 years
Query!
Eligibility
Key inclusion criteria
- women 55-80 years of age;
- post-menopausal for >=5 years;
- ambulatory.
Query!
Minimum age
55
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- malignant disease diagnosed within the previous 10 years (except basal cell cancer
that has been successfully removed);
- breast cancer within the previous 20 years;
- allergy to bisphosphonates;
- previous treatment with an intravenous bisphosphonate at any time;
- previous treatment with an oral bisphosphonate within the last 6 months, >1 month of
treatment within the last year, or >3 months of treatment within the last 2 years.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2002
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2005
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1395
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Darlinghurst
Query!
Recruitment hospital [2]
0
0
- Melbourne
Query!
Recruitment hospital [3]
0
0
- Nedlands
Query!
Recruitment hospital [4]
0
0
- St. Leonards
Query!
Recruitment hospital [5]
0
0
- Sydney
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
3084 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
6000 - Nedlands
Query!
Recruitment postcode(s) [4]
0
0
2139 - St. Leonards
Query!
Recruitment postcode(s) [5]
0
0
3129 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Montana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Nebraska
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New Mexico
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Dakota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
South Dakota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Wisconsin
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Bruxelles
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Liege
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Saskatchewan
Query!
Country [23]
0
0
Czech Republic
Query!
State/province [23]
0
0
Plzen
Query!
Country [24]
0
0
Czech Republic
Query!
State/province [24]
0
0
Praha
Query!
Country [25]
0
0
Denmark
Query!
State/province [25]
0
0
Aalborg
Query!
Country [26]
0
0
Denmark
Query!
State/province [26]
0
0
Ballerup
Query!
Country [27]
0
0
Denmark
Query!
State/province [27]
0
0
København
Query!
Country [28]
0
0
Denmark
Query!
State/province [28]
0
0
Vejle
Query!
Country [29]
0
0
Denmark
Query!
State/province [29]
0
0
Århus
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Lyon
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Orleans
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Berlin
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Bochum
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Hamburg
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Budapest
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Arenzano
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Siena
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Valeggio Sul Mincio
Query!
Country [39]
0
0
Mexico
Query!
State/province [39]
0
0
Mexico City
Query!
Country [40]
0
0
Mexico
Query!
State/province [40]
0
0
Monterrey
Query!
Country [41]
0
0
Norway
Query!
State/province [41]
0
0
Haugesund
Query!
Country [42]
0
0
Norway
Query!
State/province [42]
0
0
Oslo
Query!
Country [43]
0
0
Norway
Query!
State/province [43]
0
0
Stavanger
Query!
Country [44]
0
0
Poland
Query!
State/province [44]
0
0
Grudziadz
Query!
Country [45]
0
0
Poland
Query!
State/province [45]
0
0
Krakow
Query!
Country [46]
0
0
South Africa
Query!
State/province [46]
0
0
Cape Town
Query!
Country [47]
0
0
South Africa
Query!
State/province [47]
0
0
Pretoria
Query!
Country [48]
0
0
South Africa
Query!
State/province [48]
0
0
Sommerset West
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Barcelona
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
Madrid
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Santander
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
Aberdeen
Query!
Country [53]
0
0
United Kingdom
Query!
State/province [53]
0
0
Manchester
Query!
Country [54]
0
0
United Kingdom
Query!
State/province [54]
0
0
Newcastle Upon Tyne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will assess the efficacy and safety of intravenous administration of Bonviva
regimens in women with post-menopausal osteoporosis, compared to oral daily administration.
Patients will also receive daily supplementation with vitamin D and calcium. The anticipated
time of study treatment is 2+ years, and the target sample size is 500+ individuals.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00048074
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00048074
Download to PDF